All In Biotech

Drug Trial Radar · NCT06938867

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

A Phase 1b/2a, Randomized, Double-blind Study to Investigate Safety, Tolerability, PK, PD, and Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplantation Receiving Fluoroquinolone Prophylaxis and Harboring Fluoroquinolone-Resistant Escherichia Coli Pre-Transplant

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Dec 4, 2024

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
SNIPR Biome Aps.Industry
Sponsor type
Industry
Collaborators
U.S. Health and Human Services and Biomedical Advanced Research and Development Authority; The European Commission's DG Health Emergency Preparedness and Response Authority (DG HERA) and KfW Development Bank; Italy's Ministry of Economy and Finance; CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator); Wellcome Trust; Novo Nordisk Foundation
First posted
Apr 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2a study in allogenic hematopoietic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC levofloxacin. The study consists of two parts. Part 1 will include 24 randomized and dosed patients. Part 2 will be added with amendment 3 and will include 42 randomized and dosed patients. Thus, approximately 66 patients will be randomized 1:1 to oral dosing of SNIPR001 or matching placebo, to be taken concomitantly with SoC levofloxacin prophylaxis. Subjects will be followed until 100 days post allo-HSCT transplant.

Conditions

  • E Coli Infections
  • Allogenic Transplant Patients

Interventions

  • SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coliBiological

    SNIPR001 is a live biotherapeutic product

  • Placebo 10 mLOther

    Placebo 10 mL matching to SNIPR001 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of SNIPR001 in all patients who receive SNIPR001 or placebo in combination with standard of care (SoC) levofloxacin prophylaxisTime frame: Day 30 and 100 for endpoints 1-7 and 1-2 weeks for endpoint 8

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Not yet recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Not yet recruiting

  • Weill Cornell Medicine

    New York, New York · Recruiting

  • UPMC

    Pittsburgh, Pennsylvania · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.